Dr Reddy's Laboratories ROE 2010-2024 | RDY

Current and historical return on equity (ROE) values for Dr Reddy's Laboratories (RDY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Dr Reddy's Laboratories ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-06-30 $0.66B $3.54B 20.14%
2024-03-31 $0.67B $3.37B 21.14%
2023-12-31 $0.62B $3.22B 20.59%
2023-09-30 $0.61B $3.05B 21.13%
2023-06-30 $0.57B $2.99B 20.70%
2023-03-31 $0.55B $2.81B 20.79%
2022-12-31 $0.45B $2.66B 17.42%
2022-09-30 $0.39B $2.53B 15.35%
2022-06-30 $0.38B $2.54B 15.23%
2022-03-31 $0.31B $2.51B 12.51%
2021-12-31 $0.36B $2.55B 14.65%
2021-09-30 $0.27B $2.48B 11.17%
2021-06-30 $0.24B $2.40B 10.12%
2021-03-31 $0.24B $2.37B 10.40%
2020-12-31 $0.27B $2.32B 12.37%
2020-09-30 $0.19B $2.25B 8.82%
2020-06-30 $0.24B $2.14B 11.35%
2020-03-31 $0.26B $2.06B 12.28%
2019-12-31 $0.24B $2.08B 11.27%
2019-09-30 $0.38B $2.18B 18.56%
2019-06-30 $0.30B $2.12B 15.22%
2019-03-31 $0.27B $2.03B 14.14%
2018-12-31 $0.25B $1.95B 13.25%
2018-09-30 $0.24B $1.81B 12.48%
2018-06-30 $0.21B $1.91B 10.93%
2018-03-31 $0.15B $1.94B 7.89%
2017-12-31 $0.16B $1.94B 8.34%
2017-09-30 $0.18B $1.87B 9.42%
2017-06-30 $0.18B $1.91B 9.60%
2017-03-31 $0.19B $1.91B 10.46%
2016-12-31 $0.14B $1.78B 7.68%
2016-09-30 $0.16B $1.73B 8.55%
2016-06-30 $0.22B $1.69B 12.01%
2016-03-31 $0.30B $1.94B 15.88%
2015-12-31 $0.38B $1.94B 20.39%
2015-09-30 $0.38B $1.86B 21.34%
2015-06-30 $0.37B $1.87B 21.09%
2015-03-31 $0.36B $1.79B 21.55%
2014-12-31 $0.36B $1.67B 22.28%
2014-09-30 $0.37B $1.60B 23.94%
2014-06-30 $0.38B $1.61B 26.59%
2014-03-31 $0.35B $1.51B 26.02%
2013-12-31 $0.38B $1.38B 28.79%
2013-09-30 $0.35B $1.25B 27.14%
2013-06-30 $0.31B $1.26B 24.81%
2013-03-31 $0.31B $1.34B 25.68%
2012-12-31 $0.27B $1.24B 23.66%
2012-09-30 $0.30B $1.19B 27.60%
2012-06-30 $0.29B $1.07B 27.67%
2012-03-31 $0.29B $1.13B 27.43%
2011-12-31 $0.29B $0.98B 28.76%
2011-09-30 $0.26B $0.98B 24.67%
2011-06-30 $0.26B $1.10B 24.81%
2011-03-31 $0.25B $1.03B 24.20%
2010-12-31 $0.21B $1.07B 20.85%
2010-09-30 $0.03B $0.97B 3.61%
2010-06-30 $0.02B $0.97B 1.60%
2010-03-31 $0.02B $0.96B 2.26%
2009-12-31 $-0.21B $0.87B -23.21%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $12.399B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00